000 | 01963 a2200553 4500 | ||
---|---|---|---|
005 | 20250516164608.0 | ||
264 | 0 | _c20140331 | |
008 | 201403s 0 0 eng d | ||
022 | _a1872-8227 | ||
024 | 7 |
_a10.1016/S0168-8227(13)70014-7 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aBelhadj, Mohamed | |
245 | 0 | 0 |
_aExploring insulin analogue safety and effectiveness in a Maghrebian cohort with type 2 diabetes: results from the A₁chieve study. _h[electronic resource] |
260 |
_bDiabetes research and clinical practice _cAug 2013 |
||
300 |
_aS4-14 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Multicenter Study | ||
650 | 0 | 4 |
_aAlgeria _xepidemiology |
650 | 0 | 4 | _aAsian People |
650 | 0 | 4 |
_aBiomarkers _xblood |
650 | 0 | 4 |
_aBlood Glucose _xmetabolism |
650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xblood |
650 | 0 | 4 | _aDrug Therapy, Combination |
650 | 0 | 4 | _aDrug-Related Side Effects and Adverse Reactions |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 |
_aGlycated Hemoglobin _xmetabolism |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aHypoglycemia _xepidemiology |
650 | 0 | 4 |
_aHypoglycemic Agents _xadministration & dosage |
650 | 0 | 4 |
_aInsulin Aspart _xadministration & dosage |
650 | 0 | 4 | _aInsulin Detemir |
650 | 0 | 4 |
_aInsulin, Long-Acting _xadministration & dosage |
650 | 0 | 4 |
_aLipids _xblood |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 |
_aMorocco _xepidemiology |
650 | 0 | 4 | _aPostprandial Period |
650 | 0 | 4 | _aProspective Studies |
650 | 0 | 4 | _aQuality of Life |
650 | 0 | 4 | _aRisk Factors |
650 | 0 | 4 | _aSurveys and Questionnaires |
650 | 0 | 4 | _aTreatment Outcome |
650 | 0 | 4 |
_aTunisia _xepidemiology |
650 | 0 | 4 | _aWeight Gain |
700 | 1 | _aDahaoui, Amine | |
700 | 1 | _aJamoussi, Henda | |
700 | 1 | _aFarouqi, Ahmed | |
773 | 0 |
_tDiabetes research and clinical practice _gvol. 101 Suppl 1 _gp. S4-14 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1016/S0168-8227(13)70014-7 _zAvailable from publisher's website |
999 |
_c23016548 _d23016548 |